BMRN * Stock Overview Engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BioMarin Pharmaceutical Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioMarin Pharmaceutical Historical stock prices Current Share Price US$1,700.00 52 Week High US$1,700.00 52 Week Low US$1,497.00 Beta 0.31 1 Month Change 0% 3 Month Change 0% 1 Year Change 23.64% 3 Year Change 1.19% 5 Year Change 16.51% Change since IPO 7.89%
Recent News & Updates
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024 Oct 30
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting Sep 18
Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027 Sep 05
BioMarin Pharmaceutical Inc. Announces Management Changes Aug 21
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease Jul 25
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index Jul 03 See more updates
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2024 Oct 30
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia At 2024 International Skeletal Dysplasia Society Meeting Sep 18
Biomarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2024 and for Fiscal Year 2027 Sep 05
BioMarin Pharmaceutical Inc. Announces Management Changes Aug 21
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease Jul 25
BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Small Cap Comp Growth Index Jul 03 Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children
First quarter 2024 earnings released: EPS: US$0.47 (vs US$0.27 in 1Q 2023) Apr 25
BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024 Apr 10
Biomarin Announces Board Changes, Effective May 20, 2024 Mar 07
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024 Feb 23
Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024 Jan 12
BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023 Dec 21
Third quarter 2023 earnings released: EPS: US$0.21 (vs US$0.036 loss in 3Q 2022) Nov 06
Biomarin Pharmaceutical Inc. Announces CEO Changes Nov 04 Biomarin Pharmaceutical Inc. Announces CEO Changes
BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023 Nov 02
U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia Oct 21
Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting Sep 22
BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe Aug 31
Executive VP recently sold Mex$17m worth of stock Aug 10
Second quarter 2023 earnings released: EPS: US$0.30 (vs US$0.15 in 2Q 2022) Aug 01 Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023
Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc Jul 13
U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A Jun 30
BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program Jun 23
First quarter 2023 earnings released: EPS: US$0.27 (vs US$0.66 in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$0.76 (vs US$0.35 loss in FY 2021) Mar 01
BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 08
Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis Jan 09
BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2 Jan 04
BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A Nov 24
BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program Nov 08
BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022 Oct 27
FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A Oct 13
BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022 Oct 05
BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC) Aug 25
Insider recently sold Mex$12m worth of stock Aug 13
Second quarter 2022 earnings released: EPS: US$0.15 (vs US$0.071 in 2Q 2021) Aug 04
Biomarin Pharmaceutical Inc. Revises Earnings Guidance for the Full Year 2022 Aug 04
BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A Jun 25
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed Jun 22
BioMarin Pharmaceutical Inc. Announces Favorable Results from Global Phase 2 Study of Voxzogo™ (Vosoritide) for Injection in Infants and Young Children with Achondroplasia At the Endocrine Society Annual Meeting Jun 14
BioMarin Pharmaceutical Inc. Announces Durable Hemostatic Efficacy Maintained over 6 Years in Ongoing Phase 1 2 Study of Valoctocogene Roxaparvovec Jun 01
BioMarin Pharmaceutical Inc. Announces Executive Appointments May 06
First quarter 2022 earnings released: EPS: US$0.66 (vs US$0.096 in 1Q 2021) Apr 28
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year 2022 Apr 28
BioMarin Pharmaceutical Inc., Annual General Meeting, May 24, 2022 Apr 13
Independent Director recently sold Mex$10m worth of stock Mar 06
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 25
BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Full Year of 2022 Feb 24
BioMarin Pharmaceutical Inc. Provides Updates on Progress in Gene Therapy Programs Feb 18
BioMarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control in the Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At Two Year Analysis Jan 10
ROSEN, A LEADING LAW FIRM, Encourages BioMarin Pharmaceutical Inc. Investors to Secure Counsel Before Important December 22 Deadline in Securities Class Action Dec 08
Chairman & CEO recently sold Mex$2.8m worth of stock Dec 05
Third quarter 2021 earnings released: US$0.20 loss per share (vs US$4.33 profit in 3Q 2020) Oct 30
Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.16 loss in 2Q 2020) Jul 29
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress Jul 20
European Medicines Agency Validates Biomarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A Jul 16 BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell Midcap Growth Index
BioMarin Pharmaceutical Inc. Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close Jun 26
Independent Director Michael Grey has left the company Jun 05
European Medicines Agency Grants BioMarin Pharmaceutical Inc.'s Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A May 25
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A May 20
BioMarin Pharmaceutical Inc. Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting May 13
First quarter 2021 earnings released: EPS US$0.096 (vs US$0.45 in 1Q 2020) May 06
First quarter 2021 earnings released: EPS US$0.096 (vs US$0.45 in 1Q 2020) May 01
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Full Year of 2021 Apr 30
BioMarin Pharmaceutical Inc. Announces Data from the Open-Label Long-Term Extension of the Phase 3 Study Mar 21
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A Mar 10
BioMarin Pharmaceutical Inc. Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia Mar 05
Full year 2020 earnings released: EPS US$4.75 (vs US$0.13 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
BioMarin Pharmaceutical Inc. Appoints Maykin Ho to its Board of Directors Feb 19
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A Jan 11
New 90-day high: Mex$1,806 Jan 09
BioMarin Pharmaceutical Inc. Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study Dec 23
Investor sentiment improved over the past week Dec 17
New 90-day high: Mex$1,788 Dec 16
the Portnoy Law Firm Files Class Action Lawsuit on BioMarin Pharmaceutical Inc Nov 21
BioMarin Expands Vosoritide Clinical Program Nov 10
Third quarter 2020 earnings released: EPS US$4.33 Nov 07
Revenue beats expectations Nov 07
BioMarin Pharmaceutical Inc. Announces Revised Earnings Guidance for the Year 2020 Nov 06
Food and Drug Administration Accepts Biomarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia Nov 03
New 90-day low: Mex$1,550 Oct 31
BioMarin Pharmaceutical Inc. Sues for Violations of the Federal Securities Laws Oct 29
BioMarin Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU Oct 08
BioMarin Pharmaceutical Inc. Appoints Kevin Eggan as Head of Research and Early Development Oct 06
BioMarin Pharmaceutical Inc and Gene Therapies Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation to BMN 307 Oct 03 Pomerantz Law Firm Announces the Filing of a Class Action against BioMarin Pharmaceuticals, Inc. and Certain Officers
Independent Director recently bought Mex$22m worth of stock Sep 03 Shareholder Returns BMRN * MX Biotechs MX Market 7D 0% 0% 0% 1Y 23.6% 0% 0%
See full shareholder returns
Return vs Industry: BMRN * exceeded the MX Biotechs industry which returned 8.6% over the past year.
Return vs Market: BMRN * exceeded the MX Market which returned -3.1% over the past year.
Price Volatility Is BMRN *'s price volatile compared to industry and market? BMRN * volatility BMRN * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: BMRN *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine BMRN *'s volatility change over the past year.
About the Company BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
Show more BioMarin Pharmaceutical Inc. Fundamentals Summary How do BioMarin Pharmaceutical's earnings and revenue compare to its market cap? BMRN * fundamental statistics Market cap Mex$246.43b Earnings (TTM ) Mex$6.57b Revenue (TTM ) Mex$56.13b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BMRN * income statement (TTM ) Revenue US$2.75b Cost of Revenue US$1.31b Gross Profit US$1.44b Other Expenses US$1.12b Earnings US$322.29m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 1.69 Gross Margin 52.35% Net Profit Margin 11.71% Debt/Equity Ratio 11.0%
How did BMRN * perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/11/17 11:35 End of Day Share Price 2024/08/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources BioMarin Pharmaceutical Inc. is covered by 56 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Allen Baird Ishan Majumdar Baptista Research Huidong Wang Barclays
Show 53 more analysts 
